Next Article in Journal
Reply to Schramm, L. Comment on “Li et al. BDP1 Variants I1264M and V1347M Significantly Associated with Clinical Outcomes of Pediatric Neuroblastoma Patients Imply a New Prognostic Biomarker: A 121-Patient Cancer Genome Study. Diagnostics 2021, 11, 2364”
Next Article in Special Issue
Increased Levels of ICOS and ICOSL Are Associated to Pulmonary Arterial Hypertension in Patients Affected by Connective Tissue Diseases
Previous Article in Journal
Pilot Testing of the “Turbidimeter”, a Simple, Universal Reader Intended to Complement and Enhance Bacterial Growth Detection in Manual Blood Culture Systems in Low-Resource Settings
Previous Article in Special Issue
High-Resolution Computed Tomography and Lung Ultrasound in Patients with Systemic Sclerosis: Which One to Choose?
 
 
Review
Peer-Review Record

An Overview of Different Techniques for Improving the Treatment of Pulmonary Hypertension Secondary in Systemic Sclerosis Patients

Diagnostics 2022, 12(3), 616; https://doi.org/10.3390/diagnostics12030616
by Barbara Ruaro 1,*, Francesco Salton 1, Elisa Baratella 2, Paola Confalonieri 1, Pietro Geri 1, Riccardo Pozzan 1, Chiara Torregiani 1, Roberta Bulla 3, Marco Confalonieri 1, Marco Matucci-Cerinic 4,5 and Michael Hughes 6,7
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Reviewer 3: Anonymous
Diagnostics 2022, 12(3), 616; https://doi.org/10.3390/diagnostics12030616
Submission received: 23 January 2022 / Revised: 17 February 2022 / Accepted: 28 February 2022 / Published: 1 March 2022
(This article belongs to the Special Issue Advances in Identification and Management of Systemic Sclerosis)

Round 1

Reviewer 1 Report

the paper deals  a quick and wide overview of the diagnosis of pulmonary arterial hypertension
The paper illustrates the reader to a wide and well organised overview about the diagnosis and monitoring of pulmonary arterial hypertension

Author Response

I would like to thank the reviewer for all the comments

Reviewer 2 Report

The report of Ruaro B. et al. is well written and explores deeply the  therapies in patients affected by systemic sclerosis relative to pulmonary hypertension.

Major points to address:

  • Table 1. Even the table is detailed, it would be more comprehensive with more coincise and schematic description (for example first line Therapy: PDE5i are the first line......should be PDE5i in : -77% typical IPAH p.; 81% atypical...).. Outcome: Die for PH-related complication .. and so on...
  • Table 2 : as table 1, table 2 should be more schematic
  • Paraghaph 2 Screening procedure: line 2 WHILE should move after in particular.....after catheterization is RESERVED (USED, UTILIZED)  FOR DIAGNOSIS

Author Response

I would like to thank the reviewer for all comments 

I revised the table and I corrected the error in paragraph 2

Reviewer 3 Report

This is an elegantly written MS. No suggestions!

Author Response

I would like to thank the reviewer for the comment!

Back to TopTop